{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:31:16Z","timestamp":1788208276588,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010109","name":"Medical University of Graz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Die Polymyalgia rheumatica (rPMR) ist die zweith\u00e4ufigste entz\u00fcndlich rheumatische Erkrankung im h\u00f6heren Lebensalter. In klinischen Studien werden h\u00e4ufig die Remission und das Rezidiv als Endpunkte festgesetzt, jedoch existieren f\u00fcr diese Zust\u00e4nde noch keine einheitlichen Definitionen, was die Vergleichbarkeit von Studien erschwert. Der PMR-AS (PMR-Aktivit\u00e4tsscore) ist derzeit der einzige f\u00fcr die PMR entwickelte Composite Score, durch den neben der Remission auch eine niedrige, mittlere und hohe Krankheitsaktivit\u00e4t definiert werden. In neueren Studien wird der PMR-AS h\u00e4ufig verwendet und die niedrige Krankheitsaktivit\u00e4t als Endpunkt festgelegt. Eine Limitation des PMR-AS ist die m\u00f6gliche Beeinflussung der einzelnen Variablen durch Komorbidit\u00e4ten. Beim Einsatz von Medikamenten, welche die Interleukin-6-Achse beeinflussen, sind das C\u2011reaktive Protein (CRP) und die Blutsenkungsgeschwindigkeit (BSG) f\u00fcr die Beurteilung der Krankheitsaktivit\u00e4t der PMR nur eingeschr\u00e4nkt verwertbar. Vielversprechende alternative Biomarker sind Calprotectin und Osteopontin, die bereits bei der rheumatoiden Arthritis die Erkrankungsaktivit\u00e4t unabh\u00e4ngig vom CRP widerspiegeln konnten. Dar\u00fcber hinaus k\u00f6nnten bildgebende Verfahren wie die Sonographie, Magnetresonanztomographie und FDG(Fluordesoxyglucose)-Positronenemissionstomographie zum Monitoring der Krankheitsaktivit\u00e4t eingesetzt werden, wobei diese erst in weiteren Studien validiert werden m\u00fcssen. Die PMR-IS (PMR-Impact Scale) ist ein Composite Score zur Erfassung der Auswirkungen von PMR auf die Patient:innen. Sie wurde allerdings bisher noch nicht in klinischen Studien angewendet. Die Entwicklung von weiteren PROs (\u201epatient reported outcomes\u201c) f\u00fcr die PMR und die Definition von einheitlichen Kriterien zur Erfassung der Remission und des Rezidivs sind f\u00fcr die PMR wichtige zuk\u00fcnftige Forschungsfragen.<\/jats:p>","DOI":"10.1007\/s00393-023-01358-x","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T14:56:12Z","timestamp":1684162572000},"page":"368-379","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Methoden zur Erfassung der Krankheitsaktivit\u00e4t der Polymyalgia rheumatica","Methods for assessment of disease activity of polymyalgia rheumatica"],"prefix":"10.1007","volume":"82","author":[{"given":"Myriam","family":"Reisch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Dejaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"issue":"5","key":"1358_CR1","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.semarthrit.2020.07.005","volume":"50","author":"A Sharma","year":"2020","unstructured":"Sharma\u00a0A, Mohammad\u00a0AJ, Turesson\u00a0C (2020) Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: a systematic literature review. Semin Arthritis Rheum 50(5):1040\u20131048. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.07.005","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"1358_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3109\/03009742.2014.959047","volume":"44","author":"DJ Green","year":"2015","unstructured":"Green\u00a0DJ, Muller\u00a0S, Mallen\u00a0CD, Hider\u00a0SL (2015) Fatigue as a\u00a0precursor to polymyalgia rheumatica: an explorative retrospective cohort study. Scand J Rheumatol 44(3):219\u2013223. https:\/\/doi.org\/10.3109\/03009742.2014.959047","journal-title":"Scand J Rheumatol"},{"issue":"10103","key":"1358_CR3","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S0140-6736(17)31825-1","volume":"390","author":"MA Gonz\u00e1lez-Gay","year":"2017","unstructured":"Gonz\u00e1lez-Gay\u00a0MA, Matteson\u00a0EL, Casta\u00f1eda\u00a0S (2017) Polymyalgia rheumatica. Lancet 390(10103):1700\u20131712. https:\/\/doi.org\/10.1016\/S0140-6736(17)31825-1","journal-title":"Lancet"},{"issue":"3","key":"1358_CR4","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/s0002-9343(99)00424-6","volume":"108","author":"D Blockmans","year":"2000","unstructured":"Blockmans\u00a0D, Stroobants\u00a0S, Maes\u00a0A, Mortelmans\u00a0L (2000) Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med 108(3):246\u2013249. https:\/\/doi.org\/10.1016\/s0002-9343(99)00424-6","journal-title":"Am J Med"},{"issue":"7","key":"1358_CR5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","volume":"141","author":"R Caporali","year":"2004","unstructured":"Caporali\u00a0R et al (2004) Prednisone plus methotrexate for polymyalgia rheumatica: a\u00a0randomized, double-blind, placebo-controlled trial. Ann Intern Med 141(7):493\u2013500. https:\/\/doi.org\/10.7326\/0003-4819-141-7-200410050-00005","journal-title":"Ann Intern Med"},{"issue":"6","key":"1358_CR6","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","volume":"81","author":"M Bonelli","year":"2022","unstructured":"Bonelli\u00a0M et al (2022) Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a\u00a0phase 2\/3 randomised controlled trial. Ann Rheum Dis 81(6):838\u2013844. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221126","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1358_CR7","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/jama.2022.15459","volume":"328","author":"V Devauchelle-Pensec","year":"2022","unstructured":"Devauchelle-Pensec\u00a0V et al (2022) Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial. JAMA 328(11):1053\u20131062. https:\/\/doi.org\/10.1001\/jama.2022.15459","journal-title":"JAMA"},{"issue":"5","key":"1358_CR8","doi-asserted-by":"publisher","first-page":"R176","DOI":"10.1186\/ar3140","volume":"12","author":"F Kreiner","year":"2010","unstructured":"Kreiner\u00a0F, Galbo\u00a0H (2010) Effect of etanercept in polymyalgia rheumatica: a\u00a0randomized controlled trial. Arthritis Res Ther 12(5):R176. https:\/\/doi.org\/10.1186\/ar3140","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"1358_CR9","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s00296-012-2580-4","volume":"33","author":"JH Lee","year":"2013","unstructured":"Lee\u00a0JH et\u00a0al (2013) Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR). Rheumatol Int 33(6):1475\u20131480. https:\/\/doi.org\/10.1007\/s00296-012-2580-4","journal-title":"Rheumatol Int"},{"issue":"4","key":"1358_CR10","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00296-014-3105-0","volume":"35","author":"O Viapiana","year":"2015","unstructured":"Viapiana\u00a0O et\u00a0al (2015) Prednisone compared to methylprednisolone in the polymyalgia rheumatica treatment. Rheumatol Int 35(4):735\u2013739. https:\/\/doi.org\/10.1007\/s00296-014-3105-0","journal-title":"Rheumatol Int"},{"issue":"8","key":"1358_CR11","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","volume":"75","author":"V Devauchelle-Pensec","year":"2016","unstructured":"Devauchelle-Pensec\u00a0V et al (2016) Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a\u00a0prospective longitudinal study. Ann Rheum Dis 75(8):1506\u20131510. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208742","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1358_CR12","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1002\/art.39740","volume":"68","author":"L Lally","year":"2016","unstructured":"Lally\u00a0L, Forbess\u00a0L, Hatzis\u00a0C, Spiera\u00a0R (2016) Brief report: a prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica. Arthritis Rheumatol 68(10):2550\u20132554. https:\/\/doi.org\/10.1002\/art.39740","journal-title":"Arthritis Rheumatol"},{"key":"1358_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132948","author":"K Izumi","year":"2021","unstructured":"Izumi\u00a0K, Murata\u00a0O, Higashida-Konishi\u00a0M, Kaneko\u00a0Y, Oshima\u00a0H, Takeuchi\u00a0T (2021) Steroid-sparing effect of tocilizumab and methotrexate in patients with polymyalgia rheumatica: a retrospective cohort study. J\u00a0Clin Med. https:\/\/doi.org\/10.3390\/jcm10132948","journal-title":"J Clin Med"},{"issue":"1","key":"1358_CR14","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s13063-022-06263-3","volume":"23","author":"DE Marsman","year":"2022","unstructured":"Marsman\u00a0DE, Bolhuis\u00a0TE, den Broeder\u00a0N, den Broeder\u00a0AA, van der Maas\u00a0A (2022) PolyMyalgia rheumatica treatment with methotrexate in optimal dose in an early disease phase (PMR MODE): study protocol for a\u00a0multicenter double-blind placebo controlled trial. Trials 23(1):318. https:\/\/doi.org\/10.1186\/s13063-022-06263-3","journal-title":"Trials"},{"issue":"3","key":"1358_CR15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1136\/ard.2010.133850","volume":"70","author":"C Dejaco","year":"2011","unstructured":"Dejaco\u00a0C et al (2011) Definition of remission and relapse in polymyalgia rheumatica: data from a\u00a0literature search compared with a\u00a0Delphi-based expert consensus. Ann Rheum Dis 70(3):447\u2013453. https:\/\/doi.org\/10.1136\/ard.2010.133850","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1358_CR16","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/joim.13525","volume":"292","author":"IE Lundberg","year":"2022","unstructured":"Lundberg\u00a0IE, Sharma\u00a0A, Turesson\u00a0C, Mohammad\u00a0AJ (2022) An update on polymyalgia rheumatica. J\u00a0Intern Med 292(5):717\u2013732. https:\/\/doi.org\/10.1111\/joim.13525","journal-title":"J Intern Med"},{"issue":"5","key":"1358_CR17","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/art.22777","volume":"57","author":"A Hutchings","year":"2007","unstructured":"Hutchings\u00a0A et\u00a0al (2007) Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum 57(5):803\u2013809. https:\/\/doi.org\/10.1002\/art.22777","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1358_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1053\/sarh.2000.8366","volume":"30","author":"F Cantini","year":"2000","unstructured":"Cantini\u00a0F et al (2000) Erythrocyte sedimentation rate and C\u2011reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a\u00a0prospective follow-up study. Semin Arthritis Rheum 30(1):17\u201324. https:\/\/doi.org\/10.1053\/sarh.2000.8366","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"1358_CR19","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1111\/1756-185X.13978","volume":"23","author":"K Hattori","year":"2020","unstructured":"Hattori\u00a0K, Hirano\u00a0Y, Kojima\u00a0T (2020) Predictors of glucocorticoid-free remission in patients with polymyalgia rheumatica treated with prednisolone. Int J Rheum Dis 23(11):1581\u20131586. https:\/\/doi.org\/10.1111\/1756-185X.13978","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"1358_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/art.20901","volume":"53","author":"C Salvarani","year":"2005","unstructured":"Salvarani\u00a0C et al (2005) Acute-phase reactants and the risk of relapse\/recurrence in polymyalgia rheumatica: a\u00a0prospective followup study. Arthritis Rheum 53(1):33\u201338. https:\/\/doi.org\/10.1002\/art.20901","journal-title":"Arthritis Rheum"},{"issue":"11","key":"1358_CR21","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1136\/ard.60.11.1021","volume":"60","author":"R Caporali","year":"2001","unstructured":"Caporali\u00a0R, Montecucco\u00a0C, Epis\u00a0O, Bobbio-Pallavicini\u00a0F, Maio\u00a0T, Cimmino\u00a0MA (2001) Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a\u00a0prospective study. Ann Rheum Dis 60(11):1021\u20131024. https:\/\/doi.org\/10.1136\/ard.60.11.1021","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1358_CR22","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/ard.2003.011379","volume":"63","author":"BF Leeb","year":"2004","unstructured":"Leeb\u00a0BF, Bird\u00a0HA (2004) A disease activity score for polymyalgia rheumatica. Ann Rheum Dis 63(10):1279\u20131283. https:\/\/doi.org\/10.1136\/ard.2003.011379","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1358_CR23","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3899\/jrheum.211292","volume":"49","author":"TE Bolhuis","year":"2022","unstructured":"Bolhuis\u00a0TE, Nizet\u00a0LEA, Owen\u00a0C, den Broeder\u00a0AA, van den Ende\u00a0CHM, van der Maas\u00a0A (2022) Measurement properties of the polymyalgia rheumatica activity score: a systematic literature review. J\u00a0Rheumatol 49(6):627\u2013634. https:\/\/doi.org\/10.3899\/jrheum.211292","journal-title":"J Rheumatol"},{"issue":"3","key":"1358_CR24","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/art.22630","volume":"57","author":"A Binard","year":"2007","unstructured":"Binard\u00a0A, De Bandt\u00a0M, Berthelot\u00a0J\u2011M, Saraux\u00a0A (2007) Usefulness of the disease activity scores for polymyalgia rheumatica for predicting glucocorticoid dose changes: a\u00a0study of 243 scenarios. Arthritis Rheum 57(3):481\u2013486. https:\/\/doi.org\/10.1002\/art.22630","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1358_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/art.23338","volume":"59","author":"A Binard","year":"2008","unstructured":"Binard\u00a0A, de Bandt\u00a0M, Berthelot\u00a0J\u2011M, Saraux\u00a0A (2008) Performance of the polymyalgia rheumatica activity score for diagnosing disease flares. Arthritis Rheum 59(2):263\u2013269. https:\/\/doi.org\/10.1002\/art.23338","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1358_CR26","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/rheumatology\/kex477","volume":"57","author":"V Devauchelle-Pensec","year":"2018","unstructured":"Devauchelle-Pensec\u00a0V et al (2018) Assessing polymyalgia rheumatica activity when C\u2011reactive protein is unavailable or uninterpretable. Rheumatology 57(4):666\u2013670. https:\/\/doi.org\/10.1093\/rheumatology\/kex477","journal-title":"Rheumatology"},{"issue":"1","key":"1358_CR27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3899\/jrheum.141179","volume":"43","author":"T Helliwell","year":"2016","unstructured":"Helliwell\u00a0T et\u00a0al (2016) Development of a\u00a0provisional core domain set for polymyalgia rheumatica: report from the OMERACT 12 polymyalgia rheumatica working group. J\u00a0Rheumatol 43(1):182\u2013186. https:\/\/doi.org\/10.3899\/jrheum.141179","journal-title":"J Rheumatol"},{"issue":"9","key":"1358_CR28","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.3899\/jrheum.190575","volume":"47","author":"M Yates","year":"2020","unstructured":"Yates\u00a0M et\u00a0al (2020) Feasibility and face validity of outcome measures for use in future studies of polymyalgia rheumatica: an OMERACT study. J\u00a0Rheumatol 47(9):1379\u20131384. https:\/\/doi.org\/10.3899\/jrheum.190575","journal-title":"J Rheumatol"},{"key":"1358_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac317","author":"H Twohig","year":"2022","unstructured":"Twohig\u00a0H, Mitchell\u00a0C, Mallen\u00a0C, Muller\u00a0S (2022) Development and psychometric evaluation of the PMR-impact scale: a\u00a0new patient reported outcome measure for polymyalgia rheumatica. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keac317","journal-title":"Rheumatology"},{"issue":"8","key":"1358_CR30","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/art.23924","volume":"59","author":"L Pulsatelli","year":"2008","unstructured":"Pulsatelli\u00a0L et al (2008) Serum interleukin\u20116 receptor in polymyalgia rheumatica: a\u00a0potential marker of relapse\/recurrence risk. Arthritis Rheum 59(8):1147\u20131154. https:\/\/doi.org\/10.1002\/art.23924","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1358_CR31","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto\u00a0N, Terao\u00a0K, Mima\u00a0T, Nakahara\u00a0H, Takagi\u00a0N, Kakehi\u00a0T (2008) Mechanisms and pathologic significances in increase in serum interleukin\u20116 (IL-6) and soluble IL\u20116 receptor after administration of an anti-IL\u20116 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112(10):3959\u20133964. https:\/\/doi.org\/10.1182\/blood-2008-05-155846","journal-title":"Blood"},{"issue":"11","key":"1358_CR32","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1136\/ard.2006.051979","volume":"65","author":"M Cutolo","year":"2006","unstructured":"Cutolo\u00a0M et al (2006) Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Ann Rheum Dis 65(11):1438\u20131443. https:\/\/doi.org\/10.1136\/ard.2006.051979","journal-title":"Ann Rheum Dis"},{"key":"1358_CR33","doi-asserted-by":"publisher","first-page":"102684","DOI":"10.1016\/j.jaut.2021.102684","volume":"123","author":"JC Graver","year":"2021","unstructured":"Graver\u00a0JC et al (2021) Association of the CXCL9-CXCR3 and CXCL13-CXCR5 axes with B\u2011cell trafficking in giant cell arteritis and polymyalgia rheumatica. J\u00a0Autoimmun 123:102684. https:\/\/doi.org\/10.1016\/j.jaut.2021.102684","journal-title":"J Autoimmun"},{"issue":"9","key":"1358_CR34","doi-asserted-by":"publisher","first-page":"e23000","DOI":"10.1002\/jcla.23000","volume":"33","author":"J-Y Jung","year":"2019","unstructured":"Jung\u00a0J\u2011Y, Lee\u00a0E, Suh\u00a0C\u2011H, Kim\u00a0H\u2011A (2019) Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are associated with disease activity in polymyalgia rheumatica. J\u00a0Clin Lab Anal 33(9):e23000. https:\/\/doi.org\/10.1002\/jcla.23000","journal-title":"J Clin Lab Anal"},{"issue":"6","key":"1358_CR35","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1136\/ard.36.6.560","volume":"36","author":"W Esselinckx","year":"1977","unstructured":"Esselinckx\u00a0W, Bucknall\u00a0RC, Dixon\u00a0AS (1977) Polymyalgia rheumatica. Assessment of disease activity using erythrocyte sedimentation rate and plasma viscosity. Ann Rheum Dis 36(6):560\u2013562. https:\/\/doi.org\/10.1136\/ard.36.6.560","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1358_CR36","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1093\/rheumatology\/kep395","volume":"49","author":"SL Mackie","year":"2010","unstructured":"Mackie\u00a0SL, Hensor\u00a0EMA, Haugeberg\u00a0G, Bhakta\u00a0B, Pease\u00a0CT (2010) Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a\u00a05-year prospective study. Rheumatology 49(4):716\u2013722. https:\/\/doi.org\/10.1093\/rheumatology\/kep395","journal-title":"Rheumatology"},{"issue":"2","key":"1358_CR37","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10787-022-00932-0","volume":"30","author":"C Xu","year":"2022","unstructured":"Xu\u00a0C, Wu\u00a0Y, Liu\u00a0N (2022) Osteopontin in autoimmune disorders: current knowledge and future perspective. Inflammopharmacol 30(2):385\u2013396. https:\/\/doi.org\/10.1007\/s10787-022-00932-0","journal-title":"Inflammopharmacol"},{"issue":"2","key":"1358_CR38","doi-asserted-by":"publisher","first-page":"e000570","DOI":"10.1136\/rmdopen-2017-000570","volume":"3","author":"S Prieto-Gonz\u00e1lez","year":"2017","unstructured":"Prieto-Gonz\u00e1lez\u00a0S et al (2017) Serum osteopontin: a\u00a0biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients. RMD Open 3(2):e570. https:\/\/doi.org\/10.1136\/rmdopen-2017-000570","journal-title":"RMD Open"},{"issue":"12","key":"1358_CR39","doi-asserted-by":"publisher","first-page":"e0145468","DOI":"10.1371\/journal.pone.0145468","volume":"10","author":"K Izumi","year":"2015","unstructured":"Izumi\u00a0K, Kaneko\u00a0Y, Hashizume\u00a0M, Yoshimoto\u00a0K, Takeuchi\u00a0T (2015) Baseline serum osteopontin levels predict the clinical effectiveness of tocilizumab but not Infliximab in biologic-na\u00efve patients with rheumatoid arthritis: a single-center prospective study at 1 year (the Keio first-bio cohort study). PLoS ONE 10(12):e145468. https:\/\/doi.org\/10.1371\/journal.pone.0145468","journal-title":"PLoS ONE"},{"issue":"12","key":"1358_CR40","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1177\/0022034515605270","volume":"94","author":"SR Rittling","year":"2015","unstructured":"Rittling\u00a0SR, Singh\u00a0R (2015) Osteopontin in immune-mediated diseases. J\u00a0Dent Res 94(12):1638\u20131645. https:\/\/doi.org\/10.1177\/0022034515605270","journal-title":"J Dent Res"},{"issue":"6","key":"1358_CR41","doi-asserted-by":"publisher","first-page":"306","DOI":"10.5114\/reum.2016.64907","volume":"54","author":"M Kope\u0107-M\u0119drek","year":"2016","unstructured":"Kope\u0107-M\u0119drek\u00a0M, Widuchowska\u00a0M, Kucharz\u00a0EJ (2016) Calprotectin in rheumatic diseases: a\u00a0review. Reumatologia 54(6):306\u2013309. https:\/\/doi.org\/10.5114\/reum.2016.64907","journal-title":"Reumatologia"},{"issue":"12","key":"1358_CR42","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1093\/rheumatology\/kev251","volume":"54","author":"J Inciarte-Mundo","year":"2015","unstructured":"Inciarte-Mundo\u00a0J et al (2015) Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. Rheumatology 54(12):2239\u20132243. https:\/\/doi.org\/10.1093\/rheumatology\/kev251","journal-title":"Rheumatology"},{"issue":"7","key":"1358_CR43","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/RHU.0000000000000729","volume":"24","author":"JM Springer","year":"2018","unstructured":"Springer\u00a0JM et\u00a0al (2018) Serum S100 proteins as a\u00a0marker of disease activity in large vessel Vasculitis. J\u00a0Clin Rheumatol 24(7):393\u2013395. https:\/\/doi.org\/10.1097\/RHU.0000000000000729","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"1358_CR44","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/03009740410009931","volume":"34","author":"JG Brun","year":"2005","unstructured":"Brun\u00a0JG, Madland\u00a0TM, Gran\u00a0JT, Myklebust\u00a0G (2005) A longitudinal study of calprotectin in patients with polymyalgia rheumatica or temporal arteritis: relation to disease activity. Scand J Rheumatol 34(2):125\u2013128. https:\/\/doi.org\/10.1080\/03009740410009931","journal-title":"Scand J Rheumatol"},{"issue":"5","key":"1358_CR45","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1136\/ard.2009.113555","volume":"69","author":"M Jim\u00e9nez-Palop","year":"2010","unstructured":"Jim\u00e9nez-Palop\u00a0M et al (2010) Ultrasonographic monitoring of response to therapy in polymyalgia rheumatica. Ann Rheum Dis 69(5):879\u2013882. https:\/\/doi.org\/10.1136\/ard.2009.113555","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1358_CR46","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1093\/rheumatology\/kep286","volume":"48","author":"P Macchioni","year":"2009","unstructured":"Macchioni\u00a0P, Catanoso\u00a0MG, Pipitone\u00a0N, Boiardi\u00a0L, Salvarani\u00a0C (2009) Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica. Rheumatology 48(12):1566\u20131569. https:\/\/doi.org\/10.1093\/rheumatology\/kep286","journal-title":"Rheumatology"},{"issue":"4","key":"1358_CR47","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00259-015-3287-z","volume":"43","author":"X Palard-Novello","year":"2016","unstructured":"Palard-Novello\u00a0X et al (2016) Value of (18)F-FDG PET\/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment. Eur J Nucl Med Mol Imaging 43(4):773\u2013779. https:\/\/doi.org\/10.1007\/s00259-015-3287-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1358_CR48","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/rheumatology\/kel376","volume":"46","author":"D Blockmans","year":"2007","unstructured":"Blockmans\u00a0D, De Ceuninck\u00a0L, Vanderschueren\u00a0S, Knockaert\u00a0D, Mortelmans\u00a0L, Bobbaers\u00a0H (2007) Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a\u00a0prospective study in 35\u00a0patients. Rheumatology 46(4):672\u2013677. https:\/\/doi.org\/10.1093\/rheumatology\/kel376","journal-title":"Rheumatology"},{"issue":"12","key":"1358_CR49","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1136\/annrheumdis-2015-207395","volume":"74","author":"SL Mackie","year":"2015","unstructured":"Mackie\u00a0SL et al (2015) Whole-body MRI of patients with polymyalgia rheumatica identifies a\u00a0distinct subset with complete patient-reported response to glucocorticoids. Ann Rheum Dis 74(12):2188\u20132192. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207395","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1358_CR50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10067-021-05819-z","volume":"41","author":"A Floris","year":"2022","unstructured":"Floris\u00a0A et al (2022) Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a\u00a0systematic literature review and meta-analysis. Clin Rheumatol 41(1):19\u201331. https:\/\/doi.org\/10.1007\/s10067-021-05819-z","journal-title":"Clin Rheumatol"},{"issue":"3","key":"1358_CR51","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/1744666X.2021.1890032","volume":"17","author":"D Prieto-Pe\u00f1a","year":"2021","unstructured":"Prieto-Pe\u00f1a\u00a0D, Casta\u00f1eda\u00a0S, Atienza-Mateo\u00a0B, Blanco\u00a0R, Gonz\u00e1lez-Gay\u00a0MA (2021) Predicting the risk of relapse in polymyalgia rheumatica: novel insights. Expert Rev Clin Immunol 17(3):225\u2013232. https:\/\/doi.org\/10.1080\/1744666X.2021.1890032","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"1358_CR52","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/rheumatology\/kez261","volume":"59","author":"Y van Sleen","year":"2020","unstructured":"van Sleen\u00a0Y et al (2020) High angiopoietin\u20112 levels associate with arterial inflammation and long-term glucocorticoid requirement in polymyalgia rheumatica. Rheumatology 59(1):176\u2013184. https:\/\/doi.org\/10.1093\/rheumatology\/kez261","journal-title":"Rheumatology"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-023-01358-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-023-01358-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-023-01358-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T11:03:42Z","timestamp":1686654222000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-023-01358-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1358"],"URL":"https:\/\/doi.org\/10.1007\/s00393-023-01358-x","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"7 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Dejaco hat Vortragshonorare oder Honorare f\u00fcr Konsultationen von folgenden Firmen erhalten: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, Roche, Galapagos, Sparrow and Sanofi. Zudem Grant zur Unterst\u00fctzung von Forschungsprojekten durch AbbVie. M.\u00a0Reisch gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}